Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE GLYCOL 3500

« Back to Dashboard

Generic drugs containing POLYETHYLENE GLYCOL 3500 excipient

Company	Ingredient	NDC	Excipient
STAT RX LLC USA	mupirocin	16590-158	POLYETHYLENE GLYCOL 3500
A-S Medication Solutions	rosuvastatin calcium	50090-2805	POLYETHYLENE GLYCOL 3500

Polyethylene Glycol 3500 Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 24, 2026

Polyethylene glycol 3500, commonly grouped commercially with polyethylene glycol 3350 and macrogol 3350, is a mature, low-cost pharmaceutical excipient. Its financial profile is driven by volume, qualification status, supply reliability, and manufacturing scale rather than patent exclusivity. Public companies generally do not report PEG 3500 revenue separately, so market value must be assessed through broader polyethylene glycol, laxative, oral-solid-dose, and excipient markets.

The strongest demand comes from osmotic laxative products, oral powders, tablets, capsules, liquid formulations, and selected biologic or parenteral formulation systems. The principal commercial risks are feedstock-cost volatility, pharmaceutical-grade qualification requirements, customer switching costs, and substitution by other molecular-weight grades.

What is polyethylene glycol 3500 used for in pharmaceuticals?

PEG 3500 is a high-molecular-weight polyethylene glycol used as an excipient, osmotic agent, binder, lubricant, solubilizer, humectant, and viscosity modifier. Commercial and regulatory references often use the related terms PEG 3350, macrogol 3350, or polyethylene glycol 3350 rather than PEG 3500.

Attribute	PEG 3500 market position
Chemical class	Polyether polymer
Primary excipient role	Osmotic agent, binder, lubricant, solubilizer, viscosity modifier
Closest regulatory category	PEG 3350 or macrogol 3350
Typical dosage forms	Oral powders, tablets, capsules, liquids, semisolids
Prescription status	Excipient status depends on finished product
Patent status	No meaningful composition-of-matter exclusivity
Main commercial advantage	Established safety and broad formulation utility
Main commercial constraint	Pharmaceutical-grade consistency and qualification

PEG 3350 is used prominently in osmotic laxative products. The FDA has approved PEG 3350-containing products for constipation, including MiraLAX and prescription products containing polyethylene glycol 3350 with electrolytes. These products create demand for pharmaceutical-grade polymer but do not establish a separate proprietary market for PEG 3500 as a raw material (FDA, 2024a).

How large is the polyethylene glycol 3500 market?

No authoritative public source reports a standalone global revenue figure for PEG 3500. Suppliers generally combine PEG grades in product catalogs and financial reporting. Public market estimates that isolate PEG 3500 should therefore be treated as model-based rather than audited segment data.

The addressable market consists of several overlapping segments:

1. Pharmaceutical excipient-grade PEG.
2. Finished osmotic laxatives containing PEG 3350.
3. Oral solid-dose and liquid formulations using PEG as a functional excipient.
4. Cosmetic and personal-care PEG grades.
5. Industrial and technical polyethylene glycol products.

Pharmaceutical PEG represents a smaller volume segment than industrial PEG but has higher selling prices because of documentation, impurity controls, traceability, and regulatory qualification. The financial value of the excipient market is therefore not proportional to tonnage.

What drives PEG 3500 demand?

Demand is linked to four structural factors:

• Continued use of oral dosage forms.
• Growth in self-care constipation products.
• Expansion of generic and private-label laxative products.
• Requirement for qualified excipient suppliers in regulated markets.

Demand is less sensitive to innovation cycles than active pharmaceutical ingredients. A formulation using PEG 3350 or PEG 3500 may remain commercially viable for decades if the supplier maintains consistent specifications and the finished product retains regulatory approval.

The main volume driver is laxative use. PEG-based laxatives compete with lactulose, magnesium salts, stimulant laxatives, fiber products, and combination electrolyte preparations. PEG has a favorable position in products requiring predictable osmotic activity and a relatively neutral formulation profile.

What is the financial trajectory for PEG 3500 suppliers?

The financial trajectory is best characterized as low-to-moderate growth with margin differentiation by grade and service level.

Financial driver	Expected effect on suppliers
Pharmaceutical-grade demand	Supports stable pricing and recurring contracts
Industrial PEG oversupply	Limits pricing power in standard grades
Ethylene oxide and energy costs	Creates input-cost volatility
Regulatory qualification	Raises switching costs and protects incumbent suppliers
Laxative volume growth	Supports steady demand for PEG 3350-class material
Generic competition	Pressures finished-product prices but can increase excipient volume
Specialized grades	Improve margins relative to commodity PEG
Dual sourcing	Limits long-term customer concentration risk

Standard PEG grades face commodity pressure from large chemical manufacturers. Pharmaceutical-grade products can command a premium because customers must qualify the supplier, validate analytical methods, review change controls, and maintain regulatory documentation.

Supplier revenue is likely to grow through a combination of modest volume expansion and mix improvement. The stronger margin opportunity is in pharmaceutical-grade, low-endotoxin, low-peroxide, directly compressible, or specially controlled products rather than in undifferentiated PEG polymer.

Public financial statements from diversified chemical companies typically aggregate PEG within broader care chemicals, performance materials, or specialty ingredients businesses. They do not provide sufficient data to calculate PEG 3500 revenue, EBITDA, or operating margin independently.

Which companies supply pharmaceutical-grade PEG 3500?

The supply base includes major chemical manufacturers, excipient specialists, and regional distributors. Product nomenclature differs by supplier and may identify the material as PEG 3350, macrogol 3350, PEG 4000, or a compendial molecular-weight range.

Relevant supplier categories include:

Supplier category	Commercial role
Large chemical manufacturers	Polymer production, global capacity, bulk supply
Excipient specialists	Pharmaceutical-grade processing, documentation, technical support
Contract manufacturers	Custom blending, packing, and regional distribution
Distributors	Inventory, local registration support, and smaller-volume access

Examples of recognized PEG product families include BASF Kollisolv PEG products and Dow CARBOWAX SENTRY pharmaceutical excipients. Croda and other specialty excipient suppliers also market pharmaceutical-grade PEG materials or related excipient systems. Availability of a specific PEG 3500 or PEG 3350 grade depends on region, manufacturing site, pharmacopeial specification, and customer qualification (BASF, 2024; Dow, 2024).

Commercial buyers should distinguish between:

• Pharmaceutical grade and technical grade.
• PEG 3350 and PEG 4000.
• Powder, flake, prill, and liquid presentations.
• Low-peroxide and standard grades.
• Direct-compression and conventional excipient grades.
• Compendial and noncompendial specifications.

What regulatory status applies to PEG 3500?

PEG 3500 is regulated primarily through its use in a finished pharmaceutical product. It is not generally approved as a standalone active drug. The relevant regulatory controls apply to identity, purity, residual ethylene oxide-related impurities, peroxide content, molecular-weight distribution, water content, heavy metals, microbial quality where applicable, and manufacturing controls.

FDA status and inactive-ingredient listings

The FDA Inactive Ingredient Database identifies excipients used in approved drug products by route, dosage form, and maximum potency information where available. PEG 3350 and related polyethylene glycol grades appear in approved formulations, but an entry for one molecular-weight grade does not automatically establish approval for every PEG grade or every route of administration (FDA, 2024b).

Regulatory status depends on:

• Exact molecular-weight distribution.
• Grade and manufacturing process.
• Route of administration.
• Maximum daily exposure.
• Finished-product formulation.
• Applicable United States Pharmacopeia or European Pharmacopoeia specification.

European regulatory status

European products commonly use the term macrogol. Macrogol 3350 is established in European medicinal products, particularly laxative formulations and electrolyte preparations. European Pharmacopoeia specifications and national marketing authorizations govern the material and its finished-product use (European Directorate for the Quality of Medicines & HealthCare, 2024).

What patents protect polyethylene glycol 3500?

No material composition patent protects PEG 3500 as a mature polymer excipient. The basic polyethylene glycol composition, polymerization technology, and common excipient applications are long outside ordinary pharmaceutical patent terms.

Protection may still arise from:

• Specific finished-product formulations.
• Electrolyte combinations.
• Taste-masking systems.
• Dosage regimens.
• Powder sachet compositions.
• Manufacturing processes.
• Device or packaging configurations.
• Novel PEG conjugates used as active pharmaceutical ingredients.

These rights generally protect a particular product or use, not the sale of PEG 3500 as a raw excipient.

What is the Orange Book status of PEG 3500 products?

The FDA Orange Book lists approved drug products and patents submitted by applicants for those products. It does not list PEG 3500 as a standalone excipient product category. Orange Book patents may cover PEG-containing finished products, including formulation, method-of-use, or drug-delivery claims (FDA, 2024c).

A supplier of PEG 3500 does not normally face an Orange Book patent barrier merely because the material is incorporated into a generic product. The relevant risk falls on the finished-product sponsor.

When does PEG 3500 lose exclusivity?

PEG 3500 has no meaningful remaining molecule-level exclusivity period. The material is commercially open and can be manufactured by qualified suppliers worldwide, subject to applicable regulatory and quality requirements.

Finished PEG-based laxatives may have product-specific patents, regulatory exclusivity, or market protection. Those rights are separate from the excipient and may expire at different times. A generic applicant can generally source an equivalent PEG grade after addressing formulation, quality, bioequivalence, and regulatory requirements.

How significant are Paragraph IV challenges for PEG 3500 products?

Paragraph IV litigation risk applies to an abbreviated new drug application that challenges patents listed for a finished reference product. It does not apply to PEG 3500 as an excipient by itself.

For PEG-containing laxatives, the principal litigation issues may include:

• Whether a listed formulation patent is valid.
• Whether the generic product infringes a formulation or method patent.
• Whether the patent is properly listed in the Orange Book.
• Whether the generic product has a different electrolyte or dosing profile.
• Whether the product is submitted under an ANDA or another regulatory pathway.

The commercial importance of Paragraph IV challenges depends on product revenue. A generic challenge to a high-volume PEG laxative can affect the finished-drug sponsor while increasing demand for excipient material across multiple manufacturers.

What formulation patents protect PEG-containing products?

Formulation patents may claim more than the presence of PEG. Potential claim elements include:

• Defined PEG molecular-weight ranges.
• Electrolyte concentrations.
• Osmolarity limits.
• Flavor systems.
• Powder reconstitution properties.
• Sachet-fill composition.
• Low-volume dosing.
• Stability profiles.
• Combination therapy with other laxatives.
• Specific administration schedules.

The presence of PEG 3350 or PEG 3500 alone is usually insufficient to support a commercially durable patent position. Patent strength increases when the formulation combines a narrow composition with measurable performance advantages and a clearly defined infringement test.

Does PEG 3500 face biosimilar risk?

PEG 3500 does not face biosimilar risk. Biosimilars apply to biological medicinal products, not synthetic excipients.

A related issue exists for PEGylated biologics. In those products, PEG may be used as a conjugation component or excipient, but the patent and regulatory analysis concerns the biological active ingredient, conjugation chemistry, linker, formulation, and manufacturing process. That market is distinct from bulk PEG 3500 excipient supply.

What manufacturing and intellectual-property barriers affect PEG 3500?

The principal barriers are operational rather than patent-based.

Manufacturing controls

Manufacturers must manage:

• Ethylene oxide feedstock and process safety.
• Molecular-weight distribution.
• Residual monomers and reaction byproducts.
• Peroxide generation during storage.
• Water content and physical form.
• Batch-to-batch viscosity.
• Microbial and particulate controls where required.
• Packaging compatibility.
• Change-control documentation.

Pharmaceutical buyers often require a complete quality package, including certificates of analysis, elemental impurity controls, residual-solvent information, stability data, audit access, and change-notification commitments.

Geographic coverage

Asia has a large share of global chemical and excipient manufacturing capacity. Europe and North America retain significant demand, qualification infrastructure, and specialty-grade supply. Regional differences affect:

• Import lead times.
• Customs and registration requirements.
• Local GMP expectations.
• Distribution inventory.
• Currency exposure.
• Supply continuity.

A supplier with multiple qualified manufacturing sites has a commercial advantage in regulated markets, especially where drug manufacturers require business-continuity plans and dual sourcing.

How does PEG 3500 compare with PEG 3350 and PEG 4000?

Characteristic	PEG 3350	PEG 3500	PEG 4000
Regulatory familiarity	Very high	Often grouped with nearby grades	High in some jurisdictions
Laxative use	Extensive	Usually marketed as a comparable grade	Extensive in European products
Molecular-weight distinction	Narrow nominal grade	Commercially variable designation	Higher nominal grade
Formulation impact	Osmotic activity and texture	Similar, subject to specification	Potentially different dissolution and viscosity
Substitution ease	Requires product qualification	Requires product qualification	Requires product qualification
Patent exposure	Finished-product level	Finished-product level	Finished-product level

PEG 3500 should not be treated as automatically interchangeable with PEG 3350 or PEG 4000. Molecular-weight distribution, viscosity, dissolution, bulk density, impurity profile, and compendial compliance can affect the finished product. A formulation change may require regulatory assessment even when the chemical family remains the same.

What generic launch scenarios exist for PEG-based medicines?

Three launch scenarios are commercially relevant:

1. A generic product uses the same or closely comparable PEG grade and competes on price.
2. A private-label product uses a qualified contract manufacturer and relies on an established PEG laxative formulation.
3. A reformulated product uses a different PEG grade, flavor system, electrolyte profile, or dosing format to create a differentiated product.

The first scenario creates the highest price pressure for finished-drug sponsors but stable or rising material volume for excipient suppliers. The third scenario creates more technical-service revenue for suppliers because formulation support, analytical bridging, and regulatory documentation become important.

What licensing deals affect PEG 3500?

PEG 3500 itself is not generally licensed as a patented pharmaceutical technology. Commercial arrangements are more likely to involve:

• Long-term supply agreements.
• Preferred-supplier agreements.
• Contract manufacturing.
• Regional distribution rights.
• Technical-grade conversion to pharmaceutical grade.
• Formulation-development partnerships.

Licensing economics are more significant for PEGylated active ingredients and proprietary drug-delivery systems than for bulk PEG 3500. In the excipient market, customer retention depends on qualification, quality history, supply continuity, and price.

What is the competitive outlook for PEG 3500?

Competition is structurally high for standard material and more moderate for qualified pharmaceutical grades. The market is unlikely to produce major technology-driven price expansion because the material is mature and broadly available.

Supplier performance should be evaluated using:

• Capacity and site redundancy.
• Pharmaceutical customer concentration.
• Compendial coverage.
• Regulatory inspection history.
• Peroxide and impurity control.
• Product-change frequency.
• Geographic inventory.
• Ability to supply adjacent grades.
• Technical support for formulation changes.

The most defensible commercial position is a qualified, multi-region pharmaceutical-grade portfolio rather than a standalone PEG 3500 product.

Key Takeaways

• PEG 3500 is a mature excipient with no meaningful molecule-level patent exclusivity.
• Commercial and regulatory references often use PEG 3350 or macrogol 3350 for closely related material.
• Public companies do not generally report PEG 3500 revenue separately.
• Demand is tied mainly to osmotic laxatives, oral dosage forms, and recurring generic production.
• Pharmaceutical-grade material earns a premium through quality systems, qualification, and supply reliability.
• Orange Book and Paragraph IV risks apply to finished PEG-containing medicines, not to the excipient itself.
• Biosimilar risk is not applicable to PEG 3500.
• The strongest barriers are manufacturing consistency, impurity control, regulatory documentation, and customer qualification.
• Standard grades face commodity pricing pressure; specialized and highly controlled grades have better margin prospects.
• The financial trajectory is steady rather than disruptive, with growth driven by volume, geographic expansion, and higher-value pharmaceutical grades.

FAQs About Polyethylene Glycol 3500

Is PEG 3500 the same as PEG 3350?

No. They are closely related molecular-weight grades, but they are not automatically interchangeable. The finished-product sponsor must assess molecular-weight distribution, viscosity, dissolution, impurity profile, and regulatory impact.

Is PEG 3500 listed in the FDA Inactive Ingredient Database?

PEG-related entries may appear under PEG 3350, polyethylene glycol, or other grade-specific names. The relevant entry depends on route, dosage form, and listed use. An entry for one grade does not automatically cover every PEG grade.

Can a generic drug manufacturer change from PEG 3350 to PEG 3500?

A change may be possible, but it requires formulation, quality, stability, and regulatory assessment. The manufacturer must demonstrate that the change does not alter product performance or approved specifications.

Does PEG 3500 have a Drug Master File?

A supplier may maintain a confidential Drug Master File or equivalent quality package, but DMF availability is supplier-specific. A DMF does not create patent exclusivity and does not replace finished-product approval.

Is pharmaceutical-grade PEG 3500 more profitable than industrial PEG?

Usually, yes. Pharmaceutical-grade PEG can command a premium because of testing, documentation, qualification, and change-control requirements. The premium is offset by higher compliance costs and customer audit obligations.

References

1. BASF. (2024). Kollisolv polyethylene glycol pharmaceutical excipients. BASF SE.

2. Dow. (2024). CARBOWAX SENTRY polyethylene glycol pharmaceutical excipients. Dow Inc.

3. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Macrogols and related monographs. Council of Europe.

4. U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drug products containing polyethylene glycol 3350. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024b). Inactive Ingredient Database. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.